Invivyd, Inc. - Common Stock IVVD 深 沪
等待开盘 07-30 09:30:00 美东时间
0.8065
-0.031
-3.68%
华盛通- 最 高0.8437
- 今 开0.8437
- 成交量 51.80万股
- 最 低 0.8026
- 昨 收 0.8373
- 总市值 9678.00万
- 52周最高 2.74
- 市盈率 静 --
- 换手率 0.43%
- 52周最低 0.3546
- 委 比 -1.97%
- 总股本 1.20亿
- 历史最高 78.82
- 量 比 0.59
- 振 幅 4.91%
- 历史最低 0.3546
- 每 手 1
- 风险率 1.28%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Scientist Dr. Akiko Iwasaki Joins SPEAR Study Group to Investigate Monoclonal Antibodies for Long COVID and COVID-19 Post-Vaccination Syndrome
Invivyd, Inc. has announced the addition of Dr. Akiko Iwasaki to the SPEAR Study Group, focusing on the biology and clinical effects of the persistent SARS-CoV-2 spike antigen. Her expertise in viral pathogenesis and post-viral chronic conditions, including Long COVID and PVS, will guide the group's efforts to explore the safety and efficacy of monoclonal antibodies in treating these conditions. The SPEAR Study Group is planning clinical trials u...
07-23 11:01
Invivyd Says Updated NCCN Guidelines For Prevention And Treatment Of Cancer-Related Infections Now Recommend Use Of Available Monoclonal Antibodies For Pre-Exposure Prophylaxis Of COVID-19
NCCN Clinical Practice Guidelines in Oncology for the Prevention and Treatment of Cancer-Related Infections now recommend monoclonal antibodies for pre-exposure prophylaxis against COVID-19 in appropriate cancer
07-21 19:11
National Comprehensive Cancer Network® (NCCN®) Guidelines Recommend Monoclonal Antibodies for COVID-19 Prevention in People with Cancer; New Data Published in JAMA Oncology Underscore Severe Impact of COVID-19 on This Population
The updated NCCN guidelines now recommend monoclonal antibodies for COVID-19 prevention in cancer patients. This aligns with IDSA and CDC guidance, emphasizing their role in protecting immunocompromised individuals. New research highlights the significant impact of COVID-19 on cancer patients, including treatment delays and severe complications. Monoclonal antibodies offer targeted protection, reducing risks and ensuring continuity of care. These...
07-21 11:05
Invivyd and Leading Researchers Form SPEAR (Spike Protein Elimination and Recovery) Study Group to Assess the Effects of Monoclonal Antibody Therapy for Long COVID and COVID-19 Post-Vaccination Syndrome
Invivyd, Inc. has formed the SPEAR Study Group to evaluate the potential of monoclonal antibody therapy, including PEMGARDA (pemivibart), for treating Long COVID and Post-Vaccination Syndrome (PVS). The group, led by experts in Long COVID biology, aims to conduct rigorous clinical trials assessing the safety, efficacy, and translational biology of anti-SARS-CoV-2 spike protein antibodies in patients with persistent viral exposure. This initiative...
07-02 11:01
美股大行评级 | 潜在涨幅205.56%！康托·菲茨杰拉德上调HIVE Digital Technologies目标价至5.5美元，维持"超配"评级
<span> <meta content="no-referrer" name="referrer"></span><p>https://static-hk.hstong.com/public/forum-v2/status/icon/50267976/originalpic/1145638202455883776.png</p><span style="color:#999999;">编者按：每日追踪华尔街最新评级与目标价，挖掘潜力股投资机会。</span><blockquote> <p><span style="color:#fa1432;"><strong>今日重点评级关注</strong></span></p></blockquote><p>• 康托·菲茨杰拉德：维持HIVE Digital Technologies(HIVE)"超配"评级，目标价从5美元升至5.5美元</p> <p>• BTIG：维持Theravance Biopharma(TBPH)"买入"评
06-28 08:37
美股大行评级 | 潜在涨幅61.27%！Loop Capital上调英伟达目标价至250美元，维持"买入"评级
今日重点评级关注：Benchmark：维持特斯拉(TSLA)"买入"评级，目标价从350美元升至475美元>>
06-27 08:37
D. Boral Capital Maintains Buy on Invivyd, Maintains $9 Price Target
D. Boral Capital analyst Jason Kolbert maintains Invivyd (NASDAQ:IVVD) with a Buy and maintains $9 price target.
06-26 20:15
Invivyd Announces Full Phase 1/2 Clinical Data For VYD2311, Next-Gen Monoclonal Antibody Candidate Designed To Prevent And Treat COVID-19
Attractive safety profile demonstrated across all dosing cohorts and routes of administration (IV, SC, and IM); all reported adverse events (AEs) deemed unrelated or classified as mild to moderate and largely related to
06-26 19:04
Invivyd Announces Positive Full Phase 1/2 Clinical Data for VYD2311, a Next Generation COVID-19 Monoclonal Antibody for Potential Use as a Non-Vaccine Preventative and for Treatment of Active Infection
Invivyd, Inc. announced full Phase 1/2 clinical data for VYD2311, a next-generation monoclonal antibody (mAb) candidate designed to prevent and treat COVID-19. The trial demonstrated an attractive safety profile across all dosing cohorts and administration routes (IV, SC, IM), with all adverse events deemed mild to moderate and unrelated to the study drug. VYD2311 exhibited a long half-life, with the IM route showing the longest duration at 76 da...
06-26 11:01
美股大行评级 | 英伟达、赛富时、C3.ai、Veeva Systems等获多家机构上调目标价！
<span> <meta content="no-referrer" name="referrer"></span><p>https://static-hk.hstong.com/public/forum-v2/status/icon/50267976/originalpic/1135136987677396993.png</p><span style="color:#999999;">编者按：每日追踪华尔街最新评级与目标价，挖掘潜力股投资机会。</span><blockquote> <p><span style="color:#fa1432;"><strong>今日重点评级关注</strong></span></p></blockquote><p>• 摩根大通：维持Cogent Biosciences(COGT)"超配"评级，目标价从21美元升至25美元</p> <p>• Chardan Capital：维持Taysha Gene Therapies(TSHA)"买入"
05-30 09:09
